中文
EN
News Center
News Center
Viwit Pharmaceuticals Co., Ltd. Embarks on a New Journey: Fully Focused on Innovation, Driving the Future with Insight and Science
Author：
VIWIT
Release Time：
2026-01-29
At the Viwit 2025 Third Quarter Meeting held on October 18, 2025, Dr. Keene Y. Wei, President of the Company, delivered a keynote speech titled "Full Focus on Innovation, Guided by Insight and Science: Embarking on Viwit's New Journey of Innovation Upgrade." This marks the official launch of a brand-new development phase for Viwit. In this era of profound transformation within the pharmaceutical industry, this strategic decision embodies our deep understanding of patient needs, stems from our unwavering commitment to advancing healthcare through scientific prowess, and reflects our firm confidence in the industry's future.
An outline of Dr. Wei's speech is as follows:
PART 1: Innovation Upgrade
A Strategic Leap from Industrial Chain Foundations to an Innovative Drug R&D Ecosystem
Reflecting on Viwit's development journey, we have traversed a solid path of industrial upgrading: from "Boranes → Intermediates → APIs → Generic Drugs → Innovative Drugs." Since our founding in 2006, we have progressively built comprehensive capabilities covering the entire industry chain: R&D, production, quality, supply chain, and commercialization.
Viwit's innovation upgrade has been strategically successful, yet the journey has been arduous and challenging. We are an enterprise that has advanced step by step through self-reliance, without depending on continuous financing and "cash-burning" practices – a path filled with difficulty. At the same time, we frankly acknowledge shortcomings in tactical execution, where the return on investment for certain business segments or products has not been ideal. Precisely these experiences and lessons from practice have allowed us to accumulate a solid industrial foundation and technological reserves, while forging our core corporate spirit: "Stay Focused on the Goal, Work Hard with Perseverance, and Innovate Continuously."
PART 2: Strategic Focus
Dedicated to Innovative Drug R&D and Brand Building
Looking ahead, we will concentrate our resource allocation and R&D efforts on innovative drug development, focusing primarily on Class 1 New Drugs, supplemented by a select number of Class 2 New Drugs. Following the spin-off and independent operation of the targeted radiopharmaceuticals R&D project incubated by Viwit (now Viwit Zhike), Viwit is now fully and strategically focused on innovative drug R&D. For the generic drug sector, existing projects will continue to completion, with no new projects to be initiated thereafter.
We are committed to developing "Branded Innovative Drugs" – products rooted in solid scientific experimentation, guided by profound patient insights, and through systematic scientific knowledge dissemination, ultimately establishing stable trust and reliance in the minds of doctors and patients that transcends mere chemical/biological components. We are not just selling a "drug," but an integrated "Health Solution" and a "Trustworthy Commitment."
Regarding market strategy, we adopt a dual-channel approach combining online and offline efforts to drive market penetration. By collaborating with leading international and domestic experts from the R&D stage, we aim to build an authoritative clinical network, enhance product awareness and academic influence, and complete a comprehensive layout for subsequent drug commercialization.
PART 3: Embracing Challenges
Prioritizing Insight and Tackling Scientific Hurdles
In the new drug R&D process, we face dual challenges: cognitive and scientific.
We adhere to the principle of "Insight First." Before project initiation, we must, based on a deep understanding of health needs and scientific mechanisms, brainstorm collectively to define a clear R&D direction.
On the scientific front, we are advancing from "Simple Science Class 1" new drugs towards "Novel Science Class 1" new drugs. This demands world-class scientific comprehension capabilities in relevant fields, as well as the ability to translate that understanding into tangible results. Only by reaching the global forefront do we possess true competitiveness.
Exploring the unknown with novel science innovative drugs is exhilarating! In some cutting-edge fields, lacking ready-made literature reports and reference cases, we must delve into deep thought, conduct independent exploration, and form our own understanding. We must be adept at asking questions – posing questions itself is part of gaining insight; providing answers further deepens that insight; and verifying answers ultimately confirms our understanding.
Fully focusing on innovation presents formidable challenges. We need to continuously strengthen our Drug Discovery capabilities, particularly in biology and AI + Drug Design; simultaneously, we must establish a robust Clinical Development system to provide comprehensive support for innovative drug R&D.
PART 4: Solid Foundation
Dual Assurance from Platform Capabilities and Team Strength
In platform development, we have established international-standard production, quality, and CMC systems, providing a solid foundation for innovative drug R&D.
In team building, Viwit's most valuable asset is our team, which is also the greatest driver of innovation and development. We adhere to the principle of "Utilizing Strengths, While Also Acknowledging Weaknesses." Placing the right people in the right roles based on their strengths is a deeply ingrained concept at Viwit. Building upon this foundation, we aim to further improve by understanding weaknesses. Only by knowing our own and our team members' shortcomings can we build complementary teams, help manage risks arising from these weaknesses during work, and avoid major issues. For shortcomings in work, we seek to understand and accommodate from a higher perspective, rather than demanding perfection. While no individual is perfect, we strive to build a perfect team. Simultaneously, we value recognizing and recommending talent, continuously tapping into internal potential.
We consistently maintain a "Beginner's Mindset," continuously learning, leading change, and making a difference in the world – even if it's just a small one! Addressing unmet health needs through innovative drugs and creating social value is the profound significance of our work.
"Innovation for a Better Life" – this is not only the mission we have always upheld but also the fundamental driving force propelling us on this new journey. We are deeply aware that the path of pharmaceutical innovation is long and challenging, yet every solid step forward holds the potential to bring a positive change to patients' lives.
In the future, Viwit will march forward with firmer strides and a more open attitude, progressing steadily alongside all our partners on this promising path, and contributing our strength to pharmaceutical innovation in China and the world.